Table 1.
Clinical characteristics of patients with very severe GO (n = 14) and moderate-to-severe GO (n = 23)
| Patients with very severe GO | Patients with moderate-to-severe GO | p value* | |
|---|---|---|---|
| Graves disease | 11 | 20 | 0.83** |
| Hashimoto disease | 3 | 2 | 0.55** |
| Euthyroid Graves disease | 0 | 1 | |
| Female | 10 (71) | 15 (65) | 0.10** |
| Age, years | 57 (31–81) | 52 (24–76) | 0.10 |
| Active smokers | 8 (57) | 9 (39) | 0.64** |
| Duration of thyroid disease, weeks | 118 (9–805) | 75 (10–802) | 0.50 |
| Duration of GO, weeks | 31 (13–805) | 43 (11–478) | 0.80 |
| Duration of DON, weeks | 9 (1–25) | – | – |
| TSH (ref. range 0.270–4.200 µIU/mL) | 1.24 (0.005–14.1) | 1.27 (0.005–5.8) | 0.77 |
| fT3 (ref. range 3.1–6.8 pmol/L) | 4.46 (3.2–12.9) | 5.07 (3.7–8) | 0.50 |
| fT4 (ref. range 12–22 pmol/L) | 16.97 (7.1–23.2) | 16.94 (9.9–24.2) | 0.38 |
| TBII (ref. range <1.75 IU/L) | 14 (1.0–25) | 6.9 (0.6–40) | 0.05 |
| TPOAb (ref. range <34 IU/mL) | 51 (7–600) | 121 (7–6,000) | 0.27 |
| TgAb (ref. range <115 IU/mL) | 23 (5–4,000) | 38 (10–4,000) | 0.50 |
| CAS | 4 (2–6) | 4 (3–7) | 0.45 |
| Proptosisa, mm | 21 (16–23.5) | 22 (18–27) | 0.29 |
Data are presented as n (%) or median (range), as appropriate. GO, Graves orbitopathy; DON, dysthyroid optic neuropathy; fT3, free triiodothyronine; fT4, free thyroxine; TBII, TSH-binding inhibitory immunoglobulins; TPOAb, thyroid peroxidase antibodies; TgAb, thyroglobulin antibodies; CAS, clinical activity score.
*
Mann- Whitney U test or otherwise, as indicated
**
χ2 test.
a
Proptosis was measured with a Hertel exophthalmometer.